Asymmetric Usage of Antagonist Charged Residues Drives Interleukin-5 Receptor Recruitment but Is Insufficient for Receptor Activation†

Biochemistry - United States
doi 10.1021/bi0518038
Full Text
Abstract

Available in full text

Categories
Biochemistry
Date
Authors
Publisher

American Chemical Society (ACS)

Related search

Crucial Positively Charged Residues for Ligand Activation of the GPR35 Receptor

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2013English

Identification of Receptor-Binding Domains on Human Interleukin 5 and Design of an Interleukin 5-Derived Receptor Antagonist.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1995English

Interleukin-1, Interleukin-1 Receptor, and Interleukin-1 Receptor Antagonist

Proceedings of the Nutrition Society
MedicineNutritionDietetics
1994English

Receptor Epitope Usage by an Interleukin-5 Mimetic Peptide

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2005English

5-Ht3 Receptor Antagonism by Anpirtoline, a Mixed 5-Ht1 Receptor Agonist/5-Ht3 Receptor Antagonist

British Journal of Pharmacology
Pharmacology
1995English

Deficiency of Interleukin-1 Receptor Antagonist Responsive to Anakinra

Pediatric Dermatology
DermatologyChild HealthPediatricsPerinatology
2012English

Structure Studies of Recombinant Interleukin-1 Receptor Antagonist Protein

Acta Crystallographica Section A Foundations of Crystallography
1993English

Multiple Sclerosis: Longitudinal Measurement of Interleukin-1 Receptor Antagonist.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1997English

Arthritis Gene Therapy Using the Interleukin-1 Receptor Antagonist

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy